drugset
drugset / Trial / NCT01689233

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

NCT01689233 ↗

Phase 3 Completed 800 enrolled TauRx Therapeutics Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.

Timeline

Start
2012-10
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HYDROMETHYLTHIONINE Small molecule 100 mg —

Indications

Alzheimer disease